Business Context and Reporting Period
Company: Disc Medicine, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 10, 2023
Reporting Period: Event date of October 10, 2023
Business Context: The Company entered into an Open Market Sale Agreement (SM) with Jefferies LLC to facilitate the potential sale of its common stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital raising mechanism.
- Maximum Offering Size: Up to $59.7 million in aggregate offering price.
- Commission Fee: Up to 3.0% of gross proceeds from shares sold.
- Securities Involved: Common Stock, par value $0.0001 per share (Trading Symbol: IRON).
Material Changes
The material change reported is the execution of a definitive agreement on October 10, 2023, authorizing an "at-the-market" offering. This agreement allows the Company to issue and sell shares through Jefferies LLC acting as a sales agent or principal. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Risks
Management Commentary: The Company retains sole discretion to issue and sell shares based on market conditions and instructions provided to Jefferies. The offering will terminate upon the sale of all Placement Shares or earlier termination of the agreement.
Risks and Contingencies:
- Dilution: The sale of shares under the agreement will result in dilution to existing shareholders.
- Market Conditions: Sales are subject to market conditions and customary parameters set by the Company.
- Indemnification: The Company has agreed to indemnify Jefferies against certain liabilities under the Securities Act and the Exchange Act.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $59.7 million offering.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination clauses and price limitations.
- Confirm the status of the effective registration statement on Form S-3 (No. 333-269272) referenced in the filing.
- Monitor future 8-K filings for actual sales activity and proceeds generated under this agreement.